Prior authorization for FDA-approved PARP inhibitors in ovarian cancer
Objectives: PARP inhibitors (PARP-I) improve survival in ovarian cancer, especially in patients with germline or somatic BRCA mutations or other homologous recombination deficiency (HRD). With high efficacy and costs, insurers may enact barriers or facilitators to PARP-I. Our objective was to examin...
Main Authors: | Anna Jo Bodurtha Smith, Annie Apple, Audra Hugo, Ashley Haggerty, Emily M. Ko |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Gynecologic Oncology Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578924000146 |
Similar Items
-
Insurance and racial disparities in prior authorization in gynecologic oncology
by: Anna Jo Bodurtha Smith, et al.
Published: (2023-04-01) -
Payor Type is Associated With Increased Rates of Reoperation and Health-care Utilization Following Unicompartmental Knee Arthroplasty: A National Database Study
by: Sean B. Sequeira, MD, et al.
Published: (2023-02-01) -
The history of establishment of the US system of medical insurance and Barack Obama`s medical reform
by: Oleg Mashevs’kyj, et al.
Published: (2017-01-01) -
Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019
by: Angela Duvalyan, et al.
Published: (2021-12-01) -
Medicare and medicaid spending trends for immunomodulators prescribed for dermatologic conditions
by: Kyla N. Price, et al.
Published: (2022-01-01)